RegeneRx Biopharmaceuticals, Inc. (RGRX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 3.82 Million USD | 8.9% |
| 2021 | 3.51 Million USD | 4.12% |
| 2020 | 3.37 Million USD | 10.61% |
| 2019 | 3.05 Million USD | 22.41% |
| 2018 | 2.49 Million USD | -42.6% |
| 2017 | 4.34 Million USD | -37.32% |
| 2016 | 6.92 Million USD | -2.42% |
| 2015 | 7.1 Million USD | 166.86% |
| 2014 | 2.66 Million USD | 59.89% |
| 2013 | 1.66 Million USD | 20.6% |
| 2012 | 1.37 Million USD | 70.22% |
| 2011 | 810.65 Thousand USD | 31.46% |
| 2010 | 616.63 Thousand USD | -29.96% |
| 2009 | 880.4 Thousand USD | -33.6% |
| 2008 | 1.32 Million USD | -46.3% |
| 2007 | 2.46 Million USD | 97.64% |
| 2006 | 1.24 Million USD | 74.94% |
| 2005 | 714.12 Thousand USD | 23.14% |
| 2004 | 579.92 Thousand USD | 200.4% |
| 2003 | 193.04 Thousand USD | -18.6% |
| 2002 | 237.14 Thousand USD | 127.91% |
| 2001 | 104.05 Thousand USD | -57.61% |
| 2000 | 245.46 Thousand USD | -81.51% |
| 1999 | 1.32 Million USD | -23.26% |
| 1998 | 1.72 Million USD | -19.57% |
| 1997 | 2.15 Million USD | 10.2% |
| 1996 | 1.95 Million USD | 58.06% |
| 1995 | 1.23 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | 3.93 Million USD | 2.7% |
| 2023 Q2 | - USD | -100.0% |
| 2022 Q2 | 3.59 Million USD | 1.97% |
| 2022 FY | 3.82 Million USD | 8.9% |
| 2022 Q4 | 3.82 Million USD | 2.84% |
| 2022 Q1 | 3.52 Million USD | 0.34% |
| 2022 Q3 | 3.72 Million USD | 3.49% |
| 2021 Q3 | 3.46 Million USD | -5.51% |
| 2021 Q4 | 3.51 Million USD | 1.52% |
| 2021 FY | 3.51 Million USD | 4.12% |
| 2021 Q2 | 3.66 Million USD | 6.66% |
| 2021 Q1 | 3.43 Million USD | 1.76% |
| 2020 Q2 | 3.21 Million USD | 3.59% |
| 2020 Q1 | 3.1 Million USD | 1.77% |
| 2020 FY | 3.37 Million USD | 10.61% |
| 2020 Q4 | 3.37 Million USD | 3.43% |
| 2020 Q3 | 3.26 Million USD | 1.44% |
| 2019 FY | 3.05 Million USD | 22.41% |
| 2019 Q1 | 2.7 Million USD | 8.58% |
| 2019 Q2 | 3.02 Million USD | 11.56% |
| 2019 Q3 | 3.01 Million USD | -0.29% |
| 2019 Q4 | 3.05 Million USD | 1.34% |
| 2018 Q1 | 2.9 Million USD | -33.16% |
| 2018 FY | 2.49 Million USD | -42.6% |
| 2018 Q2 | 2.96 Million USD | 2.24% |
| 2018 Q3 | 2.44 Million USD | -17.58% |
| 2018 Q4 | 2.49 Million USD | 1.91% |
| 2017 FY | 4.34 Million USD | -37.32% |
| 2017 Q4 | 4.34 Million USD | -30.55% |
| 2017 Q3 | 6.25 Million USD | 4.24% |
| 2017 Q1 | 6.43 Million USD | -7.17% |
| 2017 Q2 | 5.99 Million USD | -6.72% |
| 2016 Q2 | 9.11 Million USD | -9.38% |
| 2016 Q1 | 10.06 Million USD | 41.73% |
| 2016 Q4 | 6.92 Million USD | -10.52% |
| 2016 FY | 6.92 Million USD | -2.42% |
| 2016 Q3 | 7.74 Million USD | -15.08% |
| 2015 FY | 7.1 Million USD | 166.86% |
| 2015 Q2 | 5.68 Million USD | 25.33% |
| 2015 Q1 | 4.53 Million USD | 70.4% |
| 2015 Q4 | 7.1 Million USD | 3.78% |
| 2015 Q3 | 6.84 Million USD | 20.4% |
| 2014 Q3 | 2.52 Million USD | -18.91% |
| 2014 FY | 2.66 Million USD | 59.89% |
| 2014 Q4 | 2.66 Million USD | 5.26% |
| 2014 Q2 | 3.11 Million USD | -11.48% |
| 2014 Q1 | 3.52 Million USD | 111.61% |
| 2013 Q3 | 1.82 Million USD | 16.19% |
| 2013 Q1 | 1.59 Million USD | 15.83% |
| 2013 FY | 1.66 Million USD | 20.6% |
| 2013 Q2 | 1.57 Million USD | -1.64% |
| 2013 Q4 | 1.66 Million USD | -8.9% |
| 2012 Q4 | 1.37 Million USD | 27.95% |
| 2012 FY | 1.37 Million USD | 70.22% |
| 2012 Q3 | 1.07 Million USD | -11.46% |
| 2012 Q1 | 1.08 Million USD | 33.83% |
| 2012 Q2 | 1.21 Million USD | 12.27% |
| 2011 Q3 | 466.59 Thousand USD | -54.67% |
| 2011 Q4 | 810.65 Thousand USD | 73.74% |
| 2011 FY | 810.65 Thousand USD | 31.46% |
| 2011 Q1 | 687.62 Thousand USD | 11.51% |
| 2011 Q2 | 1.02 Million USD | 49.68% |
| 2010 Q1 | 766.36 Thousand USD | -12.95% |
| 2010 Q4 | 616.63 Thousand USD | -46.37% |
| 2010 Q2 | 878.67 Thousand USD | 14.65% |
| 2010 Q3 | 1.14 Million USD | 30.86% |
| 2010 FY | 616.63 Thousand USD | -29.96% |
| 2009 Q3 | 830.78 Thousand USD | -42.14% |
| 2009 FY | 880.4 Thousand USD | -33.6% |
| 2009 Q4 | 880.4 Thousand USD | 5.97% |
| 2009 Q2 | 1.43 Million USD | -17.76% |
| 2009 Q1 | 1.74 Million USD | 31.68% |
| 2008 Q2 | 1.76 Million USD | 16.58% |
| 2008 Q1 | 1.51 Million USD | -38.7% |
| 2008 FY | 1.32 Million USD | -46.3% |
| 2008 Q4 | 1.32 Million USD | -18.15% |
| 2008 Q3 | 1.61 Million USD | -8.2% |
| 2007 Q4 | 2.46 Million USD | 110.58% |
| 2007 FY | 2.46 Million USD | 97.64% |
| 2007 Q2 | 1.04 Million USD | -4.79% |
| 2007 Q3 | 1.17 Million USD | 12.07% |
| 2007 Q1 | 1.09 Million USD | -12.04% |
| 2006 Q3 | 1.14 Million USD | -36.91% |
| 2006 Q4 | 1.24 Million USD | 8.69% |
| 2006 FY | 1.24 Million USD | 74.94% |
| 2006 Q1 | 736.88 Thousand USD | 3.19% |
| 2006 Q2 | 1.82 Million USD | 147.24% |
| 2005 Q3 | 533.59 Thousand USD | 100.59% |
| 2005 Q4 | 714.12 Thousand USD | 33.83% |
| 2005 Q2 | 266.02 Thousand USD | -33.2% |
| 2005 Q1 | 398.21 Thousand USD | -31.33% |
| 2005 FY | 714.12 Thousand USD | 23.14% |
| 2004 Q4 | 579.92 Thousand USD | 117.81% |
| 2004 FY | 579.92 Thousand USD | 200.4% |
| 2004 Q3 | 266.25 Thousand USD | 85.69% |
| 2004 Q2 | 143.38 Thousand USD | -41.07% |
| 2004 Q1 | 243.31 Thousand USD | 26.04% |
| 2003 Q3 | 121.53 Thousand USD | -50.1% |
| 2003 Q4 | 193.04 Thousand USD | 58.85% |
| 2003 Q1 | 143.33 Thousand USD | -39.56% |
| 2003 Q2 | 243.56 Thousand USD | 69.93% |
| 2003 FY | 193.04 Thousand USD | -18.6% |
| 2002 FY | 237.14 Thousand USD | 127.91% |
| 2002 Q4 | 237.14 Thousand USD | 101.47% |
| 2002 Q3 | 117.7 Thousand USD | 22.0% |
| 2002 Q2 | 96.47 Thousand USD | -17.62% |
| 2002 Q1 | 117.1 Thousand USD | 12.55% |
| 2001 FY | 104.05 Thousand USD | -57.61% |
| 2001 Q4 | 104.05 Thousand USD | 29.19% |
| 2001 Q3 | 80.54 Thousand USD | -60.21% |
| 2001 Q2 | 202.39 Thousand USD | -8.72% |
| 2001 Q1 | 221.73 Thousand USD | -9.67% |
| 2000 Q2 | 215.71 Thousand USD | -21.17% |
| 2000 FY | 245.46 Thousand USD | -81.51% |
| 2000 Q1 | 273.64 Thousand USD | -79.38% |
| 2000 Q3 | 206.76 Thousand USD | -4.15% |
| 2000 Q4 | 245.46 Thousand USD | 18.72% |
| 1999 FY | 1.32 Million USD | -23.26% |
| 1999 Q4 | 1.32 Million USD | 0.0% |
| 1998 Q1 | 2.4 Million USD | 11.63% |
| 1998 FY | 1.72 Million USD | -19.57% |
| 1998 Q4 | 1.73 Million USD | 0.0% |
| 1998 Q2 | 2.55 Million USD | 6.25% |
| 1997 Q1 | 1.79 Million USD | -8.21% |
| 1997 Q3 | 1.86 Million USD | 5.08% |
| 1997 Q4 | 2.15 Million USD | 15.59% |
| 1997 Q2 | 1.77 Million USD | -1.12% |
| 1997 FY | 2.15 Million USD | 10.2% |
| 1996 Q3 | 1.82 Million USD | 6.43% |
| 1996 Q1 | 1.66 Million USD | 0.0% |
| 1996 Q2 | 1.71 Million USD | 3.01% |
| 1996 FY | 1.95 Million USD | 58.06% |
| 1996 Q4 | 1.95 Million USD | 7.14% |
| 1995 FY | 1.23 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -13852.714% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 59.564% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 94.718% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -373.254% |
| Rebus Holdings, Inc. | 5.24 Million USD | 26.981% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 93.514% |
| Qrons Inc. | 1.48 Million USD | -157.111% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -212.152% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 94.891% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -8463.737% |
| Skye Bioscience, Inc. | 14.07 Million USD | 72.8% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 92.819% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 60.054% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -807.955% |
| SQZ Biotechnologies Company | 50.03 Million USD | 92.351% |
| Intellipharmaceutics International Inc. | 12 Million USD | 68.126% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 0.617% |
| Mesoblast Limited | 188.44 Million USD | 97.969% |
| Marizyme, Inc. | 26.67 Million USD | 85.651% |
| Genus plc | 485 Million USD | 99.211% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 34.487% |
| Pharming Group N.V. | 244.07 Million USD | 98.432% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -90.418% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -52.112% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -0.728% |
| ContraFect Corporation | 32.53 Million USD | 88.234% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -93.188% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | 37.93 Million USD | 89.909% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 67.502% |
| MultiCell Technologies, Inc. | 1617.67 USD | -236514.884% |
| ONE Bio Corp. | 27.49 Million USD | 86.079% |
| Accustem Sciences Inc. | 1.07 Million USD | -254.662% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 95.056% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -80.97% |
| Q BioMed Inc. | 8.13 Million USD | 52.936% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 95.385% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 25.619% |
| Biomind Labs Inc. | 1.49 Million USD | -155.413% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 96.776% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 57.669% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 79.201% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -166.947% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -2593.725% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1803.204% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 33.384% |
| GB Sciences, Inc. | 5.41 Million USD | 29.347% |
| Alpha Cognition Inc. | 7.16 Million USD | 46.577% |
| HST Global, Inc. | 593.59 Thousand USD | -544.827% |
| CSL Limited | 18.62 Billion USD | 99.979% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -203.976% |
| Halberd Corporation | 728.71 Thousand USD | -425.257% |
| Enzolytics Inc. | 365.26 Million USD | 98.952% |
| Agentix Corp. | 2.51 Million USD | -52.462% |
| Resverlogix Corp. | 67.39 Million USD | 94.321% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -356.361% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.14% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -123.317% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 84.532% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 67.843% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -4.433% |
| AVAX Technologies, Inc. | 3.99 Million USD | 4.159% |
| Zenith Capital Corp. | 27.56 Thousand USD | -13783.884% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.711% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1503.848% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -2.5% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -462.2% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -41.156% |
| Kadimastem Ltd | 3.5 Million USD | -9.21% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -5618.968% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 92.385% |
| BioStem Technologies, Inc. | 15.9 Million USD | 75.934% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -723.683% |
| LadRx Corporation | 2.2 Million USD | -73.942% |
| Cell Source, Inc. | 15.8 Million USD | 75.785% |
| Regen BioPharma, Inc. | 5.45 Million USD | 29.866% |
| Regen BioPharma, Inc. | 5.45 Million USD | 29.866% |
| NovAccess Global Inc. | 7.86 Million USD | 51.307% |
| Affymax, Inc. | 8.87 Million USD | 56.852% |
| Itoco Inc. | 1.65 Million USD | -131.537% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -86.572% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 36.723% |
| Mobile Lads Corp. | 1.31 Million USD | -191.409% |
| CytoDyn Inc. | 127.89 Million USD | 97.007% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -9057.272% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -144.363% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 65.346% |
| SYBLEU INC | 681.41 Thousand USD | -461.722% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 37.271% |
| International Stem Cell Corporation | 5.27 Million USD | 27.465% |
| Bioxytran, Inc. | 3.24 Million USD | -17.792% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -511.632% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 17.099% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 90.663% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 82.809% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -88.984% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 30.127% |
| Neutra Corp. | 973.52 Thousand USD | -293.172% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 86.808% |
| PureTech Health plc | 125.58 Million USD | 96.952% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -1.877% |
| IXICO plc | 1.9 Million USD | -101.424% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 81.355% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.295% |
| CSL Limited | 18.62 Billion USD | 99.979% |
| Cellectis S.A. | 249.36 Million USD | 98.465% |